This is a working overview of 肠促胰素, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-05. Anything still debated is marked as such rather than presented as settled.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
proteasome Also ingensin, macropain, prosome, multicatalytic proteinase, and multicatalytic endopeptidase complex. A large complex of protease enzymes that selectively degrades intracellular proteins which have been tagged for degradation by ubiquitination. Proteasomes play important roles in the timing and onset of cellular processes through the signal-mediated proteolysis of certain enzymes and regulatory proteins; they also contribute to the stress response by removing abnormal proteins and to the immune response by generating antigenic peptides.
== Further reading == Peters, U H (1992), "[Introduction of shock therapy and psychiatric emigration]", Fortschritte der Neurologie-Psychiatrie, vol. 60, no. 9 (published Sep 1992), pp. 356–365, doi:10.1055/s-2007-999155, PMID 1398417, S2CID 71208271 "Manfred J. Sakel", Journal of Clinical and Experimental Psychopathology, vol. 15, no. 3, p. 319, 1954, PMID 13221647 Fink, M (1984), "Meduna and the Origins of Convulsive Therapy", American Journal of Psychiatry, 141(9): 1034-1041 (This historical and biographical paper discusses the introduction of the shock treatment in psychiatry, the role of a theory of the biological antagonism between epilepsy and schizophrenia, and the contributions of Ladislas J. Meduna, Sakel, Ugo Cerletti, and Lucio Bini.) Doroshow, DB: Performing a Cure for Schizophrenia: Insulin Coma Therapy on the Wards. Journal of the History of Medicine and Allied Sciences, Advance Access published online on November 14, 2006 Jones, K. Insulin coma therapy in schizophrenia. J. Royal Soc. Med, 93: 147-149, 2000.
Similar delays in the MICV program meant the ultimate vehicles descending from their efforts, the M2/M3 Bradley fighting vehicle, did not enter production until 1981, by which point the Bushmaster had matured. Since 1990, there have been several enhancements made upon the weapon, resulting in the enhanced 25 mm gun. To date, more than 10,500 weapons are in service. One of the major reasons for this popularity is the extremely reliable nature of the weapon. It has a rating of 22,000 mean rounds between failure (MRBF), much higher than many comparable devices.
Sources: en.wikipedia.org
leading strand In DNA replication, the nascent strand for which both the direction of synthesis by DNA polymerase and the direction of overall chain elongation are toward the replication fork; i.e. both occur in the 5' to 3' direction, resulting in a single, continuous elongation process with few or no interruptions. By contrast, the other nascent strand, known as the lagging strand, is assembled in a discontinuous process involving the ligation of short DNA fragments synthesized in the opposite direction, away from the replication fork.
=== November 1972 meeting with Tho === On 20 November 1972, Kissinger met Tho again in Paris. Kissinger no longer aimed at secrecy and was followed by paparazzi as he went to a house owned by the French Communist Party, where Tho was waiting for him. Kissinger announced that the Americans wanted major changes to the peace agreement made in October to accommodate Thieu, which led Tho to accuse him of negotiating in bad faith. Tho stated: "We have been deceived by the French, the Japanese and the Americans. But the deception has never been so flagrant as of now". Kissinger insisted the changes he wanted were only minor, but in effect, he wanted to renegotiate almost the entire agreement. Kissinger wanted to eliminate all of the powers assigned to the National Reconciliation Council and for the National Liberation Front's Provisional Revolutionary Government to be prevented from signing the peace accords. Tho rejected Kissinger's terms, saying he would abide by the terms agreed to on 8 October. Putting more pressure on him, Nixon told Kissinger to break off the talks if Tho would not agree to the changes he wanted. Being re-elected for a second term meant that Nixon was no longer concerned about public opinion as before, and in November 1972, he seriously considered firing Kissinger. Though Nixon decided that Thieu's 69 amendments were unrealistic, he also wanted a demonstration of force to prove that he was still willing to stand by South Vietnam.
The MCH and MCHC can be confusing; in essence the MCH is a measure of the average amount of hemoglobin per red blood cell. The MCHC gives the average proportion of the cell that is hemoglobin. The MCH does not take into account the size of the red blood cells whereas the MCHC does. Collectively, the MCV, MCH, and MCHC are referred to as the red blood cell indices. Changes in these indices are visible on the blood smear: red blood cells that are abnormally large or small can be identified by comparison to the sizes of white blood cells, and cells with a low hemoglobin concentration appear pale. Another parameter is calculated from the initial measurements of red blood cells: the red blood cell distribution width or RDW, which reflects the degree of variation in the cells' size.
=== Off-label drugs === Alcohol (over-the-counter self-medication) – GABAA receptor positive allosteric modulator Atypical antipsychotics (e.g., olanzapine, quetiapine) – monoamine receptor modulators Benzodiazepines (e.g., alprazolam, chlordiazepoxide, clonazepam, diazepam, lorazepam, oxazepam) – GABAA receptor positive allosteric modulators Beta blockers (e.g., atenolol, propranolol) – β-adrenergic receptor antagonists Bupropion (Wellbutrin) – norepinephrine–dopamine reuptake inhibitor (NDRI) and nicotinic acetylcholine receptor negative allosteric modulator Cannabidiol (CBD) – cannabinoid receptor modulator and other actions, found in cannabis Gabapentinoids (e.g., gabapentin, pregabalin) – α2δ subunit-containing voltage-dependent calcium channel blockers Monoamine oxidase inhibitors (MAOIs) (e.g., phenelzine, selegiline, tranylcypromine) NMDA receptor antagonists (e.g., ketamine) Other anticonvulsants (besides gabapentinoids) (e.g., topiramate, valproic acid, tiagabine) Psychostimulants (e.g., amphetamine, methylphenidate) Selective serotonin reuptake inhibitors (SSRIs) (non-licensed) (e.g., citalopram, fluoxetine) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (non-licensed) (e.g., desvenlafaxine, duloxetine) Serotonin 5-HT1A receptor agonists (e.g., buspirone) Tricyclic antidepressants (TCAs) (e.g., clomipramine, imipramine)
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。